

References

1-38

1. Rituxan® (rituximab) package insert, Genentech, Inc., San Francisco, CA. 08/2021.
2. Wang K, Jiang Y, Zheng W, et al. Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in b-cell lymphoma. *PLoS One*. 2013;8(2):e56829.
3. Wang M, Fowler N, Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. *Leukemia*. 2013;27(9):1902-9.
4. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*. 2013;31(17):2103-2109.
5. Mok C. Rituximab for the treatment of rheumatoid arthritis: An update. *Drug Design, Development and Therapy*. 2014;8: 87-100.
6. Darwish M, Burke J, Hellriegel E, et al. An evaluation of the potential for drug—drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. *Cancer Chemotherapy and Pharmacology*. 2014;73:1119-1127.
7. Harb D, Moukadem H, Nayfe R, et al. The off-label use of rituximab for the management of inflammatory disorders: American University of Beirut Medical Center experience. *Archive of Rheumatology*. 2014;29(3):194-202.
8. Mealy M, Levy M. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. *Journal of Neuroimmunology*. 2015;287:29-30.
9. Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. *Journal of the Neurological Sciences*. 2015;351(1-2):31-35.
10. Smolen J, Landewe, Breedveld F, et al. European League Against Rheumatism's (EULAR) recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Annals of the Rheumatic Diseases*. 2014;73(3):492-509.
11. Hui-Yuen JS, Nguyen SC, Asknase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. *Lupus*. 2016;25:1086-1096.
12. Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. *PLoS ONE*. 2018;13(1): e0190425.

13. MICROMEDEX®SOLUTIONS Compendia. 2021. Rituximab.
14. MICROMEDEX®SOLUTIONS Compendia. 2021. Rituximab/Hyaluronidase Human, Recombinant.
15. Clinical Pharmacology Compendia. 2021. [database online]. Tampa FL: Gold Standard, Inc. Rituximab and Hyaluronidase.
16. Clinical Pharmacology Compendia. 2021. [database online]. Tampa FL: Gold Standard, Inc. Rituximab.
17. NCCN Drugs & Biologics Compendium™. Rituximab. 2021. National Comprehensive Cancer Network (NCCN).
18. NCCN Drugs & Biologics Compendium™. Rituximab and hyaluronidase human. 2021. National Comprehensive Cancer Network (NCCN).
19. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Annals of the Rheumatic Diseases*. Published Online First: 17 January 2014.
20. Lorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. *J Neurol*. 2015; 262(5):1115-1119.
21. Harambat J, Lamireau D, Delmas Y, et al. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. *Pediatr Crit Care Med*. 2011; 12(2):e90-e93.
22. Coiffier B, Juan-Manuel S, Jurczak W, Kim JS, Nagarkar RV, Zhavrid E, et al. Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL). *Blood*. 2016;22(128):1807.
23. Kim WS, Buske C, Kwak LW, Ogura M, Coiffier B, Lee S, et al. Similar efficacy and safety of CT-P10 and reference rituximab in patients with advanced stage follicular lymphoma: updated phase III study results. Post presented at: The American Society of Hematology Annual Meeting; December 1, 2018; San Diego, CA.
24. Ito k, Okamoto M, Inaguma Y, et al. Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. *Oncology*. 2016;91:302-310.
25. Davies A, Berge C, Boehnke A, et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. *Adv Ther*. 2017;34:2210-2231.

26. Rituxan Hycela® (rituximab and hyaluronidase human) injection for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA Revised 05/2020.
27. Ruxience (rituximab-pwr) injection, for intravenous use [package insert]. Pfizer Labs Division of Pfizer Inc. New York, New York. Revised 05/2020.
28. Truxima (rituximab-abbs) injection, for intravenous use [package insert]. Celltrion, Inc. North Wales, PA. Revised 5/2020.
29. National Comprehensive Cancer Network (NCCN). Rituximab-abbs. NCCN Drugs and Biologics Compendium®. 2021.
30. National Comprehensive Cancer Network (NCCN). Rituximab-pvvr. NCCN Drugs and Biologics Compendium®. 2021.
31. MICROMEDEX®SOLUTIONS Compendia. 2021. Rituximab-abbs.
32. MICROMEDEX®SOLUTIONS Compendia. 2021. Rituximab-pvvr.
33. Clinical Pharmacology Compendia. 2021. [database online]. Tampa FL: Gold Standard, Inc. Rituximab-abbs.
34. Clinical Pharmacology Compendia. 2021. [database online]. Tampa FL: Gold Standard, Inc. Rituximab-pwr.
35. Riabni (rituximab-arrx) injection, for intravenous use [package insert]. Amgen, Inc. Thousand Oaks, CA. Revised 12/2020.
36. Micromedex®Solutions Compendia. 2021. Rituximab-arrx.
37. National Comprehensive Cancer Network (NCCN). Rituximab-arrx. NCCN Drugs and Biologics Compendium®. 2021.